Department of Internal Medicine and Clinical Investigation Centre, Montpellier University Hospital, EA 2992, Montpellier University, Montpellier, France.
Department of Vascular Medicine, Amiens University Hospital, Amiens, France.
J Thromb Haemost. 2017 May;15(5):907-916. doi: 10.1111/jth.13664. Epub 2017 Apr 21.
Essentials Clinical significance of cancer-related isolated distal deep vein thrombosis (iDDVT) is unknown. We studied patients with iDDVT, with and without cancer, and proximal DVT with cancer. Cancer-related iDDVT patients have a much poorer prognosis than iDDVT patients without cancer. Cancer-related iDDVT patients have a similar prognosis to cancer-related proximal DVT patients.
Background Isolated distal deep vein thrombosis (iDDVT) (infra-popliteal DVT without pulmonary embolism [PE]) is a frequent event and, in the absence of cancer, is usually considered to be a minor form of venous thromboembolism (VTE). However, the clinical significance of cancer-related iDDVT is unknown. Methods Using data from the observational, prospective multicenter OPTIMEV cohort, we compared, at 3 years, the incidences of death, VTE recurrence and major bleeding in patients with cancer-related iDDVT with those in cancer patients with isolated proximal DVT (matched 1:1 on age and sex) and patients with iDDVT without cancer (matched 1:2 on age and sex). Results As compared with patients with cancer-related isolated proximal DVT (n = 92), those with cancer-related iDDVT (n = 92) had a similar risk of death (40.8% per patient-year (PY) vs. 38.3% per PY; aHR = 1.0, 95% CI[0.7-1.4]) and of major bleeding (3.8% per PY vs. 3.6% per PY, aCHR = 0.9 [0.3-3.2]) and a higher risk of VTE recurrence (5.4% per PY vs. 11.5% per PY; aCHR = 1.8 [0.7-4.5]). As compared with patients with iDDVT without cancer (n = 184), those with cancer-related iDDVT had a nine times higher risk of death (3.5% per PY vs. 38.3% per PY; aHR = 9.3 [5.5-15.9]), a higher risk of major bleeding (1.8% per PY vs. 3.6% per PY; aCHR = 2.0 [0.6-6.1]) and a higher risk of VTE recurrence (5.0% per PY vs. 11.5% per PY; aCHR = 2.0 [1.0-3.7]). The results remained similar in the subgroup of patients without history of VTE. Conclusion Patients with cancer-related iDDVT seem to have a prognosis that is similar to that of patients with cancer-related isolated proximal DVT and a dramatically poorer prognosis than patients with iDDVT without cancer. This underlines the high clinical significance of cancer-related iDDVT and the need for additional studies.
癌症相关孤立性远端深静脉血栓形成(iDDVT)的临床意义尚不清楚。我们研究了有和没有癌症的 iDDVT 患者,以及有癌症的近端深静脉血栓形成(DVT)患者。与无癌症的 iDDVT 患者相比,癌症相关 iDDVT 患者的预后要差得多。与癌症相关的近端 DVT 患者相比,癌症相关 iDDVT 患者的预后相似。
孤立性远端深静脉血栓形成(iDDVT)(无肺栓塞[PE]的 infra-popliteal DVT)是一种常见事件,在没有癌症的情况下,通常被认为是一种轻微的静脉血栓栓塞症(VTE)。然而,癌症相关 iDDVT 的临床意义尚不清楚。
利用观察性、前瞻性多中心 OPTIMEV 队列的数据,我们比较了 3 年内癌症相关 iDDVT 患者(按年龄和性别与 92 例孤立性近端 DVT 癌症患者相匹配)与无癌症 iDDVT 患者(按年龄和性别与 184 例相匹配)的死亡、VTE 复发和大出血发生率。
与癌症相关孤立性近端 DVT 患者(n = 92)相比,癌症相关 iDDVT 患者(n = 92)的死亡风险相似(患者年 40.8% vs. 38.3%;aHR = 1.0,95%CI[0.7-1.4])和大出血风险(3.8% vs. 3.6%;aCHR = 0.9 [0.3-3.2])相似,VTE 复发风险较高(5.4% vs. 11.5%;aCHR = 1.8 [0.7-4.5])。与无癌症 iDDVT 患者(n = 184)相比,癌症相关 iDDVT 患者的死亡风险高 9 倍(3.5% vs. 38.3%;aHR = 9.3 [5.5-15.9]),大出血风险高(1.8% vs. 3.6%;aCHR = 2.0 [0.6-6.1]),VTE 复发风险高(5.0% vs. 11.5%;aCHR = 2.0 [1.0-3.7])。在没有 VTE 病史的患者亚组中,结果仍然相似。
癌症相关 iDDVT 患者的预后似乎与癌症相关孤立性近端 DVT 患者相似,而与无癌症 iDDVT 患者相比,预后明显较差。这突显了癌症相关 iDDVT 的重要临床意义,并需要进一步研究。